Portal de Periódicos da CAPES

Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis

1997; Elsevier BV; Volume: 349; Issue: 9058 Linguagem: Inglês

10.1016/s0140-6736(05)62291-x

1474-547X

Franco Carmassi, Ferdinando De Negri, Marco Morale, Laura Ferrini,

Vitamin K Research Studies

In liver failure, chronic disseminated intravascular coagulation (DIC) may occur as shown by increases in markers of activation of the coagulation cascade (prothrombin fragment F1+2, thrombin-antithrombin [TAT] complexes) and fibrinolysis (plasmin-antiplasmin [PAP] complexes, D-dimer), although the contribution of impaired hepatic clearance to the increases in these products cannot be ruled out. 1 Mammen EF Coagulation defects in liver disease. Med Clin North Am. 1994; 78: 545-554 PubMed Google Scholar DIC rarely becomes life-threatening in liver cirrhosis, but chronic activation and consumption of clotting factors can contribute to haemorrhagic and thrombotic complications. 1 Mammen EF Coagulation defects in liver disease. Med Clin North Am. 1994; 78: 545-554 PubMed Google Scholar Antithrombin III (AT-III) inhibits thrombin, other activated coagulation factors, and plasmin, and previous studies suggest the usefulness of AT-III replacement in selected patients with AT-III deficiency and DIC. 2 Schipper HG ten Cate JW Antithrombin III transfusion in patients with hepatic cirrhosis. Br J Haematol. 1982; 52: 25-33 Crossref PubMed Scopus (47) Google Scholar , 3 Carmassi F Morale M De Negri F Carrai M Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis. J Mol Med. 1995; 73: 89-93 Crossref PubMed Scopus (13) Google Scholar We studied the effect of AT-III replacement therapy on coagulation and fibrinolysis in cirrhotic patients.